Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Author Correction: The temporal dynamics and infectiousness of subpatent Plasmodium falciparum infections in relation to parasite density.

Slater HC, Ross A, Felger I, Hofmann NE, Robinson L, Cook J, Gonçalves BP, Björkman A, Ouedraogo AL, Morris U, Msellem M, Koepfli C, Mueller I, Tadesse F, Gadisa E, Das S, Domingo G, Kapulu M, Midega J, Owusu-Agyei S, Nabet C, Piarroux R, Doumbo O, Doumbo SN, Koram K, Lucchi N, Udhayakumar V, Mosha J, Tiono A, Chandramohan D, Gosling R, Mwingira F, Sauerwein R, Paul R, Riley EM, White NJ, Nosten F, Imwong M, Bousema T, Drakeley C, Okell LC.

Nat Commun. 2019 Jun 11;10(1):2644. doi: 10.1038/s41467-019-10790-0.

2.

The temporal dynamics and infectiousness of subpatent Plasmodium falciparum infections in relation to parasite density.

Slater HC, Ross A, Felger I, Hofmann NE, Robinson L, Cook J, Gonçalves BP, Björkman A, Ouedraogo AL, Morris U, Msellem M, Koepfli C, Mueller I, Tadesse F, Gadisa E, Das S, Domingo G, Kapulu M, Midega J, Owusu-Agyei S, Nabet C, Piarroux R, Doumbo O, Doumbo SN, Koram K, Lucchi N, Udhayakumar V, Mosha J, Tiono A, Chandramohan D, Gosling R, Mwingira F, Sauerwein R, Paul R, Riley EM, White NJ, Nosten F, Imwong M, Bousema T, Drakeley C, Okell LC.

Nat Commun. 2019 Mar 29;10(1):1433. doi: 10.1038/s41467-019-09441-1. Erratum in: Nat Commun. 2019 Jun 11;10(1):2644.

3.

Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis.

van Eijk AM, Larsen DA, Kayentao K, Koshy G, Slaughter DEC, Roper C, Okell LC, Desai M, Gutman J, Khairallah C, Rogerson SJ, Hopkins Sibley C, Meshnick SR, Taylor SM, Ter Kuile FO.

Lancet Infect Dis. 2019 May;19(5):546-556. doi: 10.1016/S1473-3099(18)30732-1. Epub 2019 Mar 25.

4.

Emerging implications of policies on malaria treatment: genetic changes in the Pfmdr-1 gene affecting susceptibility to artemether-lumefantrine and artesunate-amodiaquine in Africa.

Okell LC, Reiter LM, Ebbe LS, Baraka V, Bisanzio D, Watson OJ, Bennett A, Verity R, Gething P, Roper C, Alifrangis M.

BMJ Glob Health. 2018 Oct 19;3(5):e000999. doi: 10.1136/bmjgh-2018-000999. eCollection 2018.

5.

The Relative Contribution of Symptomatic and Asymptomatic Plasmodium vivax and Plasmodium falciparum Infections to the Infectious Reservoir in a Low-Endemic Setting in Ethiopia.

Tadesse FG, Slater HC, Chali W, Teelen K, Lanke K, Belachew M, Menberu T, Shumie G, Shitaye G, Okell LC, Graumans W, van Gemert GJ, Kedir S, Tesfaye A, Belachew F, Abebe W, Mamo H, Sauerwein R, Balcha T, Aseffa A, Yewhalaw D, Gadisa E, Drakeley C, Bousema T.

Clin Infect Dis. 2018 Jun 1;66(12):1883-1891. doi: 10.1093/cid/cix1123.

6.

Assessing the impact of imperfect adherence to artemether-lumefantrine on malaria treatment outcomes using within-host modelling.

Challenger JD, Bruxvoort K, Ghani AC, Okell LC.

Nat Commun. 2017 Nov 9;8(1):1373. doi: 10.1038/s41467-017-01352-3.

7.

Model citizen - Authors' reply.

Brady OJ, Slater HC, Pemberton-Ross P, Wenger E, Maude RJ, Ghani AC, Penny MA, Gerardin J, White LJ, Chitnis N, Aguas R, Hay SI, Smith DL, Stuckey EM, Okiro EA, Smith TA, Okell LC.

Lancet Glob Health. 2017 Oct;5(10):e974. doi: 10.1016/S2214-109X(17)30338-8. No abstract available.

8.
9.
10.

Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study.

Brady OJ, Slater HC, Pemberton-Ross P, Wenger E, Maude RJ, Ghani AC, Penny MA, Gerardin J, White LJ, Chitnis N, Aguas R, Hay SI, Smith DL, Stuckey EM, Okiro EA, Smith TA, Okell LC.

Lancet Glob Health. 2017 Jul;5(7):e680-e687. doi: 10.1016/S2214-109X(17)30220-6. Epub 2017 May 26.

11.

Generating the evidence base for malaria elimination: the situation in Haiti.

Okell LC, Churcher TS.

Lancet Glob Health. 2017 Jan;5(1):e16-e17. doi: 10.1016/S2214-109X(16)30241-8. Epub 2016 Nov 26. No abstract available.

12.

Mathematical Modelling to Guide Drug Development for Malaria Elimination.

Slater HC, Okell LC, Ghani AC.

Trends Parasitol. 2017 Mar;33(3):175-184. doi: 10.1016/j.pt.2016.09.004. Epub 2016 Oct 7. Review.

13.

Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa.

Slater HC, Griffin JT, Ghani AC, Okell LC.

Malar J. 2016 Jan 6;15:10. doi: 10.1186/s12936-015-1075-7.

14.

Comparison of diagnostics for the detection of asymptomatic Plasmodium falciparum infections to inform control and elimination strategies.

Wu L, van den Hoogen LL, Slater H, Walker PG, Ghani AC, Drakeley CJ, Okell LC.

Nature. 2015 Dec 3;528(7580):S86-93. doi: 10.1038/nature16039.

15.

Seasonality in malaria transmission: implications for case-management with long-acting artemisinin combination therapy in sub-Saharan Africa.

Cairns ME, Walker PG, Okell LC, Griffin JT, Garske T, Asante KP, Owusu-Agyei S, Diallo D, Dicko A, Cisse B, Greenwood BM, Chandramohan D, Ghani AC, Milligan PJ.

Malar J. 2015 Aug 19;14:321. doi: 10.1186/s12936-015-0839-4.

16.

Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis.

Okell LC, Cairns M, Griffin JT, Ferguson NM, Tarning J, Jagoe G, Hugo P, Baker M, D'Alessandro U, Bousema T, Ubben D, Ghani AC.

Nat Commun. 2014 Nov 26;5:5606. doi: 10.1038/ncomms6606.

17.

The potential impact of adding ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study.

Slater HC, Walker PG, Bousema T, Okell LC, Ghani AC.

J Infect Dis. 2014 Dec 15;210(12):1972-80. doi: 10.1093/infdis/jiu351. Epub 2014 Jun 20.

PMID:
24951826
18.

Factors determining the occurrence of submicroscopic malaria infections and their relevance for control.

Okell LC, Bousema T, Griffin JT, Ouédraogo AL, Ghani AC, Drakeley CJ.

Nat Commun. 2012;3:1237. doi: 10.1038/ncomms2241.

19.

From intervention to impact: modelling the potential mortality impact achievable by different long-lasting, insecticide-treated net delivery strategies.

Okell LC, Paintain LS, Webster J, Hanson K, Lines J.

Malar J. 2012 Sep 13;11:327. doi: 10.1186/1475-2875-11-327.

20.

The potential contribution of mass treatment to the control of Plasmodium falciparum malaria.

Okell LC, Griffin JT, Kleinschmidt I, Hollingsworth TD, Churcher TS, White MJ, Bousema T, Drakeley CJ, Ghani AC.

PLoS One. 2011;6(5):e20179. doi: 10.1371/journal.pone.0020179. Epub 2011 May 24.

21.

Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies.

Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hinsley W, Bousema T, Drakeley CJ, Ferguson NM, Basáñez MG, Ghani AC.

PLoS Med. 2010 Aug 10;7(8). pii: e1000324. doi: 10.1371/journal.pmed.1000324.

22.

Neutralization of malaria glycosylphosphatidylinositol in vitro by serum IgG from malaria-exposed individuals.

de Souza JB, Runglall M, Corran PH, Okell LC, Kumar S, Gowda DC, Couper KN, Riley EM.

Infect Immun. 2010 Sep;78(9):3920-9. doi: 10.1128/IAI.00359-10. Epub 2010 Jun 21.

23.

Long-lived antibody and B Cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax.

Wipasa J, Suphavilai C, Okell LC, Cook J, Corran PH, Thaikla K, Liewsaree W, Riley EM, Hafalla JC.

PLoS Pathog. 2010 Feb 19;6(2):e1000770. doi: 10.1371/journal.ppat.1000770.

24.

Submicroscopic infection in Plasmodium falciparum-endemic populations: a systematic review and meta-analysis.

Okell LC, Ghani AC, Lyons E, Drakeley CJ.

J Infect Dis. 2009 Nov 15;200(10):1509-17. doi: 10.1086/644781. Review.

PMID:
19848588
25.

Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity.

Okell LC, Drakeley CJ, Bousema T, Whitty CJ, Ghani AC.

PLoS Med. 2008 Nov 25;5(11):e226; discussion e226. doi: 10.1371/journal.pmed.0050226.

26.

Early motherhood and mental health in midlife: a study of British and American cohorts.

Henretta JC, Grundy EM, Okell LC, Wadsworth ME.

Aging Ment Health. 2008 Sep;12(5):605-14. doi: 10.1080/13607860802343084.

27.

Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials.

Okell LC, Drakeley CJ, Ghani AC, Bousema T, Sutherland CJ.

Malar J. 2008 Jul 9;7:125. doi: 10.1186/1475-2875-7-125.

Supplemental Content

Loading ...
Support Center